目的：建立高效液相色谱法测定气管炎颗粒中黄芩苷的含量。方法采用HPLC法，色谱柱：ZORBAX SB-C18柱（4．6 mm ×150 mm ，5μm），以甲醇-0．1％磷酸（47∶53）为流动相，流速为1 ml／min ，检测波长为280 nm。结果黄芩苷在6．63...目的：建立高效液相色谱法测定气管炎颗粒中黄芩苷的含量。方法采用HPLC法，色谱柱：ZORBAX SB-C18柱（4．6 mm ×150 mm ，5μm），以甲醇-0．1％磷酸（47∶53）为流动相，流速为1 ml／min ，检测波长为280 nm。结果黄芩苷在6．63～210μg／ml范围内呈良好线性关系（r＝0.9998，n＝6），平均加样回收率为98.16％，RSD为1．89％。结论本法简便、灵敏、准确、重复性好，结果可靠，可有效地控制气管炎颗粒的质量。展开更多
To observe the therapeutic effects of a Chinese drug Bufei Keli (补肺颗粒 granules for invigorating the lung) in the treatment of chronic bronchitis at remission stage, 62 cases were randomly divided into a treatment ...To observe the therapeutic effects of a Chinese drug Bufei Keli (补肺颗粒 granules for invigorating the lung) in the treatment of chronic bronchitis at remission stage, 62 cases were randomly divided into a treatment group (treated with Bufei Keli) and a control group (treated with Yupingfeng Keli 玉屏风颗粒). The results turned out to be that the short-term clinically controlled and markedly effective rate was 77.42% and the long-term relapse-resisting markedly effective rate was 74.2% in the treatment group, which were obviously higher than 45.16% and 38.71% respectively in the control group (P<0.05). And the increase in contents of SOD and CD_3 and the decrease in LPO content in the treatment group were also bigger than that in the control group (P<0.01). It is therefore concluded that Bufei Keli can improve qi deficiency syndrome and raise the immunity of patients with chronic bronchitis, hence its effect of resisting relapse of chronic bronchitis.展开更多
文摘目的：建立高效液相色谱法测定气管炎颗粒中黄芩苷的含量。方法采用HPLC法，色谱柱：ZORBAX SB-C18柱（4．6 mm ×150 mm ，5μm），以甲醇-0．1％磷酸（47∶53）为流动相，流速为1 ml／min ，检测波长为280 nm。结果黄芩苷在6．63～210μg／ml范围内呈良好线性关系（r＝0.9998，n＝6），平均加样回收率为98.16％，RSD为1．89％。结论本法简便、灵敏、准确、重复性好，结果可靠，可有效地控制气管炎颗粒的质量。
文摘To observe the therapeutic effects of a Chinese drug Bufei Keli (补肺颗粒 granules for invigorating the lung) in the treatment of chronic bronchitis at remission stage, 62 cases were randomly divided into a treatment group (treated with Bufei Keli) and a control group (treated with Yupingfeng Keli 玉屏风颗粒). The results turned out to be that the short-term clinically controlled and markedly effective rate was 77.42% and the long-term relapse-resisting markedly effective rate was 74.2% in the treatment group, which were obviously higher than 45.16% and 38.71% respectively in the control group (P<0.05). And the increase in contents of SOD and CD_3 and the decrease in LPO content in the treatment group were also bigger than that in the control group (P<0.01). It is therefore concluded that Bufei Keli can improve qi deficiency syndrome and raise the immunity of patients with chronic bronchitis, hence its effect of resisting relapse of chronic bronchitis.
